Interferon Alpha 2a

Interferons are potent cytokines that possess antiviral, immunomodulating and antiproliferative actions. The interferons bind to specific cell-surface receptors that initiate a series of intracellular events, induction of certain enzymes, inhibition of cell-proliferation, and enhancement of immune activities. The term "interferon alfa" actually refers to at least three compounds that only differ slightly in their amino acid sequence: interferon alfa-2a, interferon alfa-2b , and interferon alfa-n3. Interferon alfa-2a, highly purified protein produced by a recombinant DNA process. interferon alpha 2a is indicated in the treatment of a variety of tumors including hairy cell leukemia, malignant melanoma, follicular lymphoma and AIDS related Kaposi`s sarcoma. Interferon alfa-2a was approved by the FDA in 1986.

Interferon Alpha 2a is primarily indicated in conditions like AIDS-related Kaposi sarcoma, Chronic hepatitis B infection, Chronic hepatitis C, Chronic myeloid leukemia, Cutaneous T cell lymphoma, Hairy cell leukemia.

Interferon Alpha 2a is contraindicated in conditions like Autoimmune hepatitis, Hypersensitivity to any component of product.

The severe or irreversible adverse effects of Interferon Alpha 2a, which give rise to further complications include Alopecia, Fever, Anemia, Confusion, Drowsiness, Vasculitis, Neutropenia, Chest pain, Cough, Myalgia, Blurred vision, Myocardial infarction, Leukopenia, Diabetes mellitus. Interferon Alpha 2a produces potentially life-threatening effects which include Infection, Ischemic damage. which are responsible for the discontinuation of Interferon Alpha 2a therapy. The symptomatic adverse reactions produced by Interferon Alpha 2a are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Vertigo, Irritability, Anorexia, Insomnia, Dry mouth, Dry skin, Weight loss, Wheezing, Nausea, vomiting, sweating, and diarrhea (when ingested ), Difficulty breathing, Hives.

Use cautiously in: thyroid disorders; bone marrow depression; hepatic, renal, or cardiac disease; pancreatitis; autoimmune disorders; pulmonary disorders; colitis; ophthalmic disorders; depression elderly patients pregnant or breastfeeding patients children younger than age 18.

Drug should not be given to Pediatrics, Pregnant Mothers, and Neonates. If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

No adult dosage information is recorded for this medicine yet.

No child dosage information is recorded for this medicine yet.

No neonatal dosage information is recorded for this medicine yet.

No data regarding the interactions of Interferon Alpha 2a was found.

No storage information is recorded for this medicine yet.